{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.5","upperLimit":"44.4","value":"29.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"}],"units":"Participants"}],"description":"OS was defined as the time from the date of first treatment to the date of death, regardless of the cause of death. OS was estimated by Kaplan-Meier method and 95% CI was assessed using the method of Brookmeyer and Crowley. Participants who did not die were censored at the date last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on safety population.","reportingStatus":"POSTED","timeFrame":"Baseline up to death from any cause (up to approximately 4 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}